Logo 1 Logo 2

Investigational Drug Details

Drug ID: D146
Drug Name: Aminocaproic acid
Synonyms:
Type: small molecule
DrugBank ID: DB00513
DrugBank Description: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
PubChem ID: 564
CasNo: 60-32-2
Repositioning for NAFLD: Yes
SMILES: NCCCCCC(O)=O
Structure:
InChiKey: SLXKOJJOQWFEFD-UHFFFAOYSA-N
Molecular Weight: 131.1729
DrugBank Targets: Plasminogen; Tissue-type plasminogen activator; Apolipoprotein(a)
DrugBank MoA: Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein(a) have been shown to increase the risk of vascular disease. Lipoprotein 9a)a has two components, apolipoprotein B-100, linked to apolipoprotein (a). Aminocaproic acid may change the conformation of apoliprotein (a), changing its binding properties and potentially preventing the formation of lipoprotein (a).
DrugBank Pharmacology: Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Aminocaproic acid may be a possible prophylactic for vascular disease, as it may prevent formation of lipoprotein (a), a risk factor for vascular disease.
DrugBank Indication: For use in the treatment of excessive postoperative bleeding.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: